Review



mouse anti human anti ccr7 percp  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems mouse anti human anti ccr7 percp
    Characterization of M1- and M2-related phenotypes. Median fluorescence intensity corresponding to (a) M1-related markers TNF- α , IDO enzyme, <t>CCR7,</t> and CD86 and (b) M2-related markers IL-10, arginase I, CD36, and CD163, found in cells harvested from all different polarizing treatments and controls and analyzed by flow cytometry. For THP-1, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2: PMA + IL-4 + IL-13; and M2 w/o PMA: IL-4 + IL-13. For U937, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2-A: PMA + IL-4 + IL-13; M2-B: PMA + M-CSF; and M2-C: IL-4 + IL-13. For primary monocytes, mock: no stimulated cells; M1: GM-CSF + LPS + INF- γ ; and M2: M-CSF + IL-4 + IL-13. Asterisks and bars denote statistical significance between conditions. Significant differences ( p ≤ 0.05) found were as follows: in THP-1 cells CD86, M1 versus M2; IL-10, mock versus all the rest of the conditions; arginase I, M1 versus PMA and versus M2 without PMA; CD163, PMA versus all the rest of the conditions and M2 versus M2 without PMA. In U937 cells IDO, M2-A versus mock and versus M2-C; CD86, (PMA, M1, M2-A, and M2-B) versus mock and M2-C; CD163, M1 versus mock and versus M2-C. In primary monocytes IDO and CD86 were significantly different in M1 versus mock and versus M2.
    Mouse Anti Human Anti Ccr7 Percp, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 101 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+anti+ccr7+percp/Mouse+anti-Human+IgM+Fc+Secondary+Antibody+(CH2)+%5BPerCP%5D/pmc04916292-70-42-48
    Average 93 stars, based on 101 article reviews
    mouse anti human anti ccr7 percp - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "Monocyte Differentiation towards Protumor Activity Does Not Correlate with M1 or M2 Phenotypes"

    Article Title: Monocyte Differentiation towards Protumor Activity Does Not Correlate with M1 or M2 Phenotypes

    Journal: Journal of Immunology Research

    doi: 10.1155/2016/6031486

    Characterization of M1- and M2-related phenotypes. Median fluorescence intensity corresponding to (a) M1-related markers TNF- α , IDO enzyme, CCR7, and CD86 and (b) M2-related markers IL-10, arginase I, CD36, and CD163, found in cells harvested from all different polarizing treatments and controls and analyzed by flow cytometry. For THP-1, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2: PMA + IL-4 + IL-13; and M2 w/o PMA: IL-4 + IL-13. For U937, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2-A: PMA + IL-4 + IL-13; M2-B: PMA + M-CSF; and M2-C: IL-4 + IL-13. For primary monocytes, mock: no stimulated cells; M1: GM-CSF + LPS + INF- γ ; and M2: M-CSF + IL-4 + IL-13. Asterisks and bars denote statistical significance between conditions. Significant differences ( p ≤ 0.05) found were as follows: in THP-1 cells CD86, M1 versus M2; IL-10, mock versus all the rest of the conditions; arginase I, M1 versus PMA and versus M2 without PMA; CD163, PMA versus all the rest of the conditions and M2 versus M2 without PMA. In U937 cells IDO, M2-A versus mock and versus M2-C; CD86, (PMA, M1, M2-A, and M2-B) versus mock and M2-C; CD163, M1 versus mock and versus M2-C. In primary monocytes IDO and CD86 were significantly different in M1 versus mock and versus M2.
    Figure Legend Snippet: Characterization of M1- and M2-related phenotypes. Median fluorescence intensity corresponding to (a) M1-related markers TNF- α , IDO enzyme, CCR7, and CD86 and (b) M2-related markers IL-10, arginase I, CD36, and CD163, found in cells harvested from all different polarizing treatments and controls and analyzed by flow cytometry. For THP-1, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2: PMA + IL-4 + IL-13; and M2 w/o PMA: IL-4 + IL-13. For U937, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2-A: PMA + IL-4 + IL-13; M2-B: PMA + M-CSF; and M2-C: IL-4 + IL-13. For primary monocytes, mock: no stimulated cells; M1: GM-CSF + LPS + INF- γ ; and M2: M-CSF + IL-4 + IL-13. Asterisks and bars denote statistical significance between conditions. Significant differences ( p ≤ 0.05) found were as follows: in THP-1 cells CD86, M1 versus M2; IL-10, mock versus all the rest of the conditions; arginase I, M1 versus PMA and versus M2 without PMA; CD163, PMA versus all the rest of the conditions and M2 versus M2 without PMA. In U937 cells IDO, M2-A versus mock and versus M2-C; CD86, (PMA, M1, M2-A, and M2-B) versus mock and M2-C; CD163, M1 versus mock and versus M2-C. In primary monocytes IDO and CD86 were significantly different in M1 versus mock and versus M2.

    Techniques Used: Fluorescence, Flow Cytometry

    Related Articles

    Incubation:

    Article Title: Monocyte Differentiation towards Protumor Activity Does Not Correlate with M1 or M2 Phenotypes
    Article Snippet: .. After incubation in the blocking solution 100 μ L of a 1 : 100 dilution in blocking solution of antibodies was added (for panel 1 staining: mouse anti-human anti-CD86-PE and anti-CD163-peridinin chlorophyll protein complex (PerCP); for panel 2 staining: rat anti-human anti-CD36-fluorescein and mouse anti-human anti-CCR7-PerCP; all antibodies from R&D Systems) and incubated at 4°C for 30 minutes. .. Cells were then washed once with 1 mL of washing buffer, fixed, and permeated with 200 μ L of Fixation/Permeabilization Solution (BD Biosciences, San Jose, CA, USA) and incubated at 4°C for 20 minutes.

    Blocking Assay:

    Article Title: Monocyte Differentiation towards Protumor Activity Does Not Correlate with M1 or M2 Phenotypes
    Article Snippet: .. After incubation in the blocking solution 100 μ L of a 1 : 100 dilution in blocking solution of antibodies was added (for panel 1 staining: mouse anti-human anti-CD86-PE and anti-CD163-peridinin chlorophyll protein complex (PerCP); for panel 2 staining: rat anti-human anti-CD36-fluorescein and mouse anti-human anti-CCR7-PerCP; all antibodies from R&D Systems) and incubated at 4°C for 30 minutes. .. Cells were then washed once with 1 mL of washing buffer, fixed, and permeated with 200 μ L of Fixation/Permeabilization Solution (BD Biosciences, San Jose, CA, USA) and incubated at 4°C for 20 minutes.

    Staining:

    Article Title: Monocyte Differentiation towards Protumor Activity Does Not Correlate with M1 or M2 Phenotypes
    Article Snippet: .. After incubation in the blocking solution 100 μ L of a 1 : 100 dilution in blocking solution of antibodies was added (for panel 1 staining: mouse anti-human anti-CD86-PE and anti-CD163-peridinin chlorophyll protein complex (PerCP); for panel 2 staining: rat anti-human anti-CD36-fluorescein and mouse anti-human anti-CCR7-PerCP; all antibodies from R&D Systems) and incubated at 4°C for 30 minutes. .. Cells were then washed once with 1 mL of washing buffer, fixed, and permeated with 200 μ L of Fixation/Permeabilization Solution (BD Biosciences, San Jose, CA, USA) and incubated at 4°C for 20 minutes.



    Similar Products

    90
    Becton Dickinson mouse anti-human ccr7 percp-cy5.5 150503
    Memory Phenotypes of Tfh Subsets during Infection (A) cTfh (PD1 + CXCR5 + CD4) cells were differentiated into memory phenotypes based on CD45RA and <t>CCR7</t> expression into central memory (CM CD45RA − CCR7 + ), effector memory (EM CD45RA − CCR7 − ), terminal differentiated effector memory (TEMRA CD45RA + CCR7 − ), and naive (CD45RA + CCR7 + ) phenotypes. (B) cTfh subsets (Th1, Th2, Th17, based on CXCR3 and CCR6 expression) had different distributions of memory phenotypes. (C) Mean memory phenotypes across subsets at day 0, before inoculation. (D) Proportion of CM and EM phenotypes within cTfh subsets after infection. Flow cytometry-based assays were performed once on cryopreserved PBMC samples tested in singles. Data are from 6 individual study participants from days 0, 8, and EOS (cryopreserved PBMC day 14/15 samples were not available). (A) and (B) are representative data from 1 individual. (C) is the median of each memory phenotype in each subset. (D) Boxplots are Tukey style, with median and IQR. Whiskers are to data point no further than 1.5 × IQR, dots are outlying points. Paired data are joined by lines. Wilcoxon signed-rank test compared to day 0 are indicated.
    Mouse Anti Human Ccr7 Percp Cy5.5 150503, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+anti+ccr7+percp/streptavidin+pe/pmc07762767-37-0-7
    Average 90 stars, based on 1 article reviews
    mouse anti-human ccr7 percp-cy5.5 150503 - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    93
    R&D Systems mouse anti human anti ccr7 percp
    Characterization of M1- and M2-related phenotypes. Median fluorescence intensity corresponding to (a) M1-related markers TNF- α , IDO enzyme, <t>CCR7,</t> and CD86 and (b) M2-related markers IL-10, arginase I, CD36, and CD163, found in cells harvested from all different polarizing treatments and controls and analyzed by flow cytometry. For THP-1, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2: PMA + IL-4 + IL-13; and M2 w/o PMA: IL-4 + IL-13. For U937, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2-A: PMA + IL-4 + IL-13; M2-B: PMA + M-CSF; and M2-C: IL-4 + IL-13. For primary monocytes, mock: no stimulated cells; M1: GM-CSF + LPS + INF- γ ; and M2: M-CSF + IL-4 + IL-13. Asterisks and bars denote statistical significance between conditions. Significant differences ( p ≤ 0.05) found were as follows: in THP-1 cells CD86, M1 versus M2; IL-10, mock versus all the rest of the conditions; arginase I, M1 versus PMA and versus M2 without PMA; CD163, PMA versus all the rest of the conditions and M2 versus M2 without PMA. In U937 cells IDO, M2-A versus mock and versus M2-C; CD86, (PMA, M1, M2-A, and M2-B) versus mock and M2-C; CD163, M1 versus mock and versus M2-C. In primary monocytes IDO and CD86 were significantly different in M1 versus mock and versus M2.
    Mouse Anti Human Anti Ccr7 Percp, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+anti+ccr7+percp/Mouse+anti-Human+IgM+Fc+Secondary+Antibody+(CH2)+%5BPerCP%5D/pmc04916292-70-42-48
    Average 93 stars, based on 1 article reviews
    mouse anti human anti ccr7 percp - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    90
    Becton Dickinson mouse anti-human ccr7 mabs conjugated percp-cy5.5
    Characterization of M1- and M2-related phenotypes. Median fluorescence intensity corresponding to (a) M1-related markers TNF- α , IDO enzyme, <t>CCR7,</t> and CD86 and (b) M2-related markers IL-10, arginase I, CD36, and CD163, found in cells harvested from all different polarizing treatments and controls and analyzed by flow cytometry. For THP-1, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2: PMA + IL-4 + IL-13; and M2 w/o PMA: IL-4 + IL-13. For U937, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2-A: PMA + IL-4 + IL-13; M2-B: PMA + M-CSF; and M2-C: IL-4 + IL-13. For primary monocytes, mock: no stimulated cells; M1: GM-CSF + LPS + INF- γ ; and M2: M-CSF + IL-4 + IL-13. Asterisks and bars denote statistical significance between conditions. Significant differences ( p ≤ 0.05) found were as follows: in THP-1 cells CD86, M1 versus M2; IL-10, mock versus all the rest of the conditions; arginase I, M1 versus PMA and versus M2 without PMA; CD163, PMA versus all the rest of the conditions and M2 versus M2 without PMA. In U937 cells IDO, M2-A versus mock and versus M2-C; CD86, (PMA, M1, M2-A, and M2-B) versus mock and M2-C; CD163, M1 versus mock and versus M2-C. In primary monocytes IDO and CD86 were significantly different in M1 versus mock and versus M2.
    Mouse Anti Human Ccr7 Mabs Conjugated Percp Cy5.5, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+anti+ccr7+percp/streptavidin+pe/pmc03839582-105-18-28
    Average 90 stars, based on 1 article reviews
    mouse anti-human ccr7 mabs conjugated percp-cy5.5 - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Becton Dickinson mouse anti-human ccr7 mabs conjugated with percp-cy5.5
    Characterization of M1- and M2-related phenotypes. Median fluorescence intensity corresponding to (a) M1-related markers TNF- α , IDO enzyme, <t>CCR7,</t> and CD86 and (b) M2-related markers IL-10, arginase I, CD36, and CD163, found in cells harvested from all different polarizing treatments and controls and analyzed by flow cytometry. For THP-1, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2: PMA + IL-4 + IL-13; and M2 w/o PMA: IL-4 + IL-13. For U937, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2-A: PMA + IL-4 + IL-13; M2-B: PMA + M-CSF; and M2-C: IL-4 + IL-13. For primary monocytes, mock: no stimulated cells; M1: GM-CSF + LPS + INF- γ ; and M2: M-CSF + IL-4 + IL-13. Asterisks and bars denote statistical significance between conditions. Significant differences ( p ≤ 0.05) found were as follows: in THP-1 cells CD86, M1 versus M2; IL-10, mock versus all the rest of the conditions; arginase I, M1 versus PMA and versus M2 without PMA; CD163, PMA versus all the rest of the conditions and M2 versus M2 without PMA. In U937 cells IDO, M2-A versus mock and versus M2-C; CD86, (PMA, M1, M2-A, and M2-B) versus mock and M2-C; CD163, M1 versus mock and versus M2-C. In primary monocytes IDO and CD86 were significantly different in M1 versus mock and versus M2.
    Mouse Anti Human Ccr7 Mabs Conjugated With Percp Cy5.5, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+human+anti+ccr7+percp/streptavidin+pe/pmc03839582-60-19-29
    Average 90 stars, based on 1 article reviews
    mouse anti-human ccr7 mabs conjugated with percp-cy5.5 - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    Memory Phenotypes of Tfh Subsets during Infection (A) cTfh (PD1 + CXCR5 + CD4) cells were differentiated into memory phenotypes based on CD45RA and CCR7 expression into central memory (CM CD45RA − CCR7 + ), effector memory (EM CD45RA − CCR7 − ), terminal differentiated effector memory (TEMRA CD45RA + CCR7 − ), and naive (CD45RA + CCR7 + ) phenotypes. (B) cTfh subsets (Th1, Th2, Th17, based on CXCR3 and CCR6 expression) had different distributions of memory phenotypes. (C) Mean memory phenotypes across subsets at day 0, before inoculation. (D) Proportion of CM and EM phenotypes within cTfh subsets after infection. Flow cytometry-based assays were performed once on cryopreserved PBMC samples tested in singles. Data are from 6 individual study participants from days 0, 8, and EOS (cryopreserved PBMC day 14/15 samples were not available). (A) and (B) are representative data from 1 individual. (C) is the median of each memory phenotype in each subset. (D) Boxplots are Tukey style, with median and IQR. Whiskers are to data point no further than 1.5 × IQR, dots are outlying points. Paired data are joined by lines. Wilcoxon signed-rank test compared to day 0 are indicated.

    Journal: Cell Reports Medicine

    Article Title: Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection

    doi: 10.1016/j.xcrm.2020.100157

    Figure Lengend Snippet: Memory Phenotypes of Tfh Subsets during Infection (A) cTfh (PD1 + CXCR5 + CD4) cells were differentiated into memory phenotypes based on CD45RA and CCR7 expression into central memory (CM CD45RA − CCR7 + ), effector memory (EM CD45RA − CCR7 − ), terminal differentiated effector memory (TEMRA CD45RA + CCR7 − ), and naive (CD45RA + CCR7 + ) phenotypes. (B) cTfh subsets (Th1, Th2, Th17, based on CXCR3 and CCR6 expression) had different distributions of memory phenotypes. (C) Mean memory phenotypes across subsets at day 0, before inoculation. (D) Proportion of CM and EM phenotypes within cTfh subsets after infection. Flow cytometry-based assays were performed once on cryopreserved PBMC samples tested in singles. Data are from 6 individual study participants from days 0, 8, and EOS (cryopreserved PBMC day 14/15 samples were not available). (A) and (B) are representative data from 1 individual. (C) is the median of each memory phenotype in each subset. (D) Boxplots are Tukey style, with median and IQR. Whiskers are to data point no further than 1.5 × IQR, dots are outlying points. Paired data are joined by lines. Wilcoxon signed-rank test compared to day 0 are indicated.

    Article Snippet: Mouse anti-human CCR7 PerCP-Cy5.5 (Clone 150503) , BD Biosciences , Cat#561144; RRID: AB_10562553.

    Techniques: Infection, Expressing, Flow Cytometry

    Journal: Cell Reports Medicine

    Article Title: Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection

    doi: 10.1016/j.xcrm.2020.100157

    Figure Lengend Snippet:

    Article Snippet: Mouse anti-human CCR7 PerCP-Cy5.5 (Clone 150503) , BD Biosciences , Cat#561144; RRID: AB_10562553.

    Techniques: In Vitro, Recombinant, Binding Assay, Purification, Software

    Characterization of M1- and M2-related phenotypes. Median fluorescence intensity corresponding to (a) M1-related markers TNF- α , IDO enzyme, CCR7, and CD86 and (b) M2-related markers IL-10, arginase I, CD36, and CD163, found in cells harvested from all different polarizing treatments and controls and analyzed by flow cytometry. For THP-1, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2: PMA + IL-4 + IL-13; and M2 w/o PMA: IL-4 + IL-13. For U937, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2-A: PMA + IL-4 + IL-13; M2-B: PMA + M-CSF; and M2-C: IL-4 + IL-13. For primary monocytes, mock: no stimulated cells; M1: GM-CSF + LPS + INF- γ ; and M2: M-CSF + IL-4 + IL-13. Asterisks and bars denote statistical significance between conditions. Significant differences ( p ≤ 0.05) found were as follows: in THP-1 cells CD86, M1 versus M2; IL-10, mock versus all the rest of the conditions; arginase I, M1 versus PMA and versus M2 without PMA; CD163, PMA versus all the rest of the conditions and M2 versus M2 without PMA. In U937 cells IDO, M2-A versus mock and versus M2-C; CD86, (PMA, M1, M2-A, and M2-B) versus mock and M2-C; CD163, M1 versus mock and versus M2-C. In primary monocytes IDO and CD86 were significantly different in M1 versus mock and versus M2.

    Journal: Journal of Immunology Research

    Article Title: Monocyte Differentiation towards Protumor Activity Does Not Correlate with M1 or M2 Phenotypes

    doi: 10.1155/2016/6031486

    Figure Lengend Snippet: Characterization of M1- and M2-related phenotypes. Median fluorescence intensity corresponding to (a) M1-related markers TNF- α , IDO enzyme, CCR7, and CD86 and (b) M2-related markers IL-10, arginase I, CD36, and CD163, found in cells harvested from all different polarizing treatments and controls and analyzed by flow cytometry. For THP-1, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2: PMA + IL-4 + IL-13; and M2 w/o PMA: IL-4 + IL-13. For U937, mock: no stimulated cells; PMA: PMA-only control; M1: PMA + LPS + INF- γ ; M2-A: PMA + IL-4 + IL-13; M2-B: PMA + M-CSF; and M2-C: IL-4 + IL-13. For primary monocytes, mock: no stimulated cells; M1: GM-CSF + LPS + INF- γ ; and M2: M-CSF + IL-4 + IL-13. Asterisks and bars denote statistical significance between conditions. Significant differences ( p ≤ 0.05) found were as follows: in THP-1 cells CD86, M1 versus M2; IL-10, mock versus all the rest of the conditions; arginase I, M1 versus PMA and versus M2 without PMA; CD163, PMA versus all the rest of the conditions and M2 versus M2 without PMA. In U937 cells IDO, M2-A versus mock and versus M2-C; CD86, (PMA, M1, M2-A, and M2-B) versus mock and M2-C; CD163, M1 versus mock and versus M2-C. In primary monocytes IDO and CD86 were significantly different in M1 versus mock and versus M2.

    Article Snippet: After incubation in the blocking solution 100 μ L of a 1 : 100 dilution in blocking solution of antibodies was added (for panel 1 staining: mouse anti-human anti-CD86-PE and anti-CD163-peridinin­chlorophyll protein complex (PerCP); for panel 2 staining: rat anti-human anti-CD36-fluorescein and mouse anti-human anti-CCR7-PerCP; all antibodies from R&D Systems) and incubated at 4°C for 30 minutes.

    Techniques: Fluorescence, Flow Cytometry